Topical Capsaicin for Pain from Chemotherapy-Induced Neuropathy

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

Recruiting Early Phase 1 Interventional Study
Peripheral Neuropathy Due to Chemotherapy
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Supportive Care
Participants needed
20 (estimated)
Sponsor
M.D. Anderson Cancer Center · Other
Who this trial is looking for

This trial is looking for people with pain in their legs caused by chemotherapy. Participants will use a cream that contains capsaicin to see if it helps reduce their pain and improve their walking.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have pain in my lower legs from chemotherapy lasting more than 90 days.
  • I have a pain score of 4 or higher on a scale of 0 to 10.
  • I am 18 years old or older.
  • I completed my chemotherapy in the past year.

You may not be able to join if

  • I have cognitive dysfunction.
  • I have a history of drug or alcohol abuse in the last 6 months.
  • I have an open skin wound or am on antibiotics for an infection.
  • I am allergic to capsaicin or adhesives.
  • I am pregnant.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Participants diagnosed with pain of the lower extremity from chronic (\>90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds), seen at MD Anderson Cancer Center * Participants reporting baseline pain ≥ 4 (0-10 scale,…
Contacts

Saba Javed, MD

713-792-9530

sjaved@mdanderson.org

CONTACT